Resmetirom Maintains MASH Efficacy Regardless of Concurrent Diabetes Therapy, Weight Loss Enhances Response
核心洞察
A secondary analysis of the MAESTRO-NASH phase 3 trial demonstrates that resmetirom's efficacy in treating metabolic-dysfunction associated steatohepatitis (搜索) (MASH (搜索)) remains consistent regardless of concurrent GLP-1 receptor agonist (搜索) or SGLT2 inhibitor (搜索) therapy.
Patients achieving at least 5% weight loss during treatment experienced significantly enhanced MASH (搜索) resolution rates, with 56.6% response in the resmetirom 100 mg group compared to 33.8% in those with minimal weight loss.
The findings support the safe and effective combination of resmetirom with commonly used diabetes medications, providing important guidance for treating MASH (搜索) patients with type 2 diabetes (搜索).
A prespecified analysis of the phase 3 MAESTRO-NASH trial reveals that resmetirom maintains consistent efficacy for metabolic-dysfunction associated steatohepatitis (搜索) (MASH (搜索)) regardless of concurrent diabetes therapy, while modest weight loss significantly enhances treatment outcomes. The findings, published in Alimentary Pharmacology & Therapeutics, provide crucial insights for clinicians treating MASH patients with type 2 diabetes (搜索).
Consistent Efficacy Across Diabetes Therapies
Among 966 randomized patients in the MAESTRO-NASH trial, approximately two-thirds had type 2 diabetes (搜索), with 21% taking GLP-1 receptor agonists and 20% using SGLT2 inhibitors at baseline. Despite these patients presenting with more advanced metabolic disease and higher cardiovascular risk, resmetirom's therapeutic activity remained intact across all subgroups.
The analysis found no evidence that GLP-1 or SGLT2 inhibitor (搜索) use altered resmetirom's efficacy. Among patients on stable GLP-1 RA therapy, MASH (搜索) resolution rates with resmetirom 100 mg reached 39%, closely mirroring the 38% response among patients not taking GLP-1 agents. Fibrosis (搜索) improvement followed the same pattern, with nearly identical response rates across both subgroups.
"For patients with T2DM, the rates of MASH (搜索) resolution and fibrosis (搜索) improvement were comparable between those who were treated with GLP-1 RA and SGLT2i and resmetirom and those who received resmetirom alone," investigators concluded.
Weight Loss Amplifies Treatment Benefits
While background diabetes therapies did not modify resmetirom's effects, patients achieving at least 5% weight loss experienced dramatically enhanced outcomes. In the resmetirom 100 mg group, patients with ≥5% weight loss achieved 56.6% MASH (搜索) resolution rates (28.4% placebo-corrected difference; 95% CI, 10.3% to 46.5%) compared to 33.8% in those with minimal weight loss (26.5% placebo-corrected difference; 95% CI, 20.1% to 32.9%).
For fibrosis (搜索) improvement, the 100 mg resmetirom group showed 40.6% response rates (12.0% placebo-corrected difference; 95% CI, −5.0% to 29.0%) in patients with ≥5% weight loss versus 31.5% (16.7% placebo-corrected difference; 95% CI, 9.9% to 23.5%) in those with <5% weight loss.
Enhanced Imaging and Non-Invasive Markers
The benefits of weight loss extended to imaging biomarkers and non-invasive tests. Patients with ≥5% weight loss in the resmetirom 100 mg group achieved up to 69% reduction in MRI-proton density fat fraction (MRI-PDFF) compared to 46% in those with minimal weight change. Liver stiffness reduction also showed greater improvement (−4.6 kPa vs −2.3 kPa) after 52 weeks of treatment.
Nearly 65% of weight-loss responders in the resmetirom 100 mg group achieved at least a 25% reduction in liver stiffness on VCTE elastography at 52 weeks, compared with less than 45% among those who lost under 5%.
Independent Mechanisms with Additive Benefits
A mediation analysis confirmed that resmetirom's improvement in MASH (搜索) and fibrosis (搜索) operates independently of weight loss but is enhanced by it. Weight change contributed little to the drug's direct effect, meaning resmetirom remains effective regardless of weight trends, but patients who do lose weight experience additive therapeutic gains.
"Relatively small amounts (≥ 5%) of weight loss enhance the effects of resmetirom on MASH (搜索) resolution, liver fibrosis (搜索) improvement, and non-invasive tests of efficacy, suggesting a potential complementary mechanism to increase response rates to resmetirom treatment," the researchers noted.
Safety Profile Maintained
Safety outcomes remained consistent across all metabolic subgroups. Gastrointestinal side effects, such as diarrhea and nausea, were slightly more common with resmetirom but were not intensified by GLP-1 RA use, despite their overlapping side-effect profiles.
The study included patients with baseline fibrosis (搜索) stages of F1B, F2, or F3 and NAFLD Activity Score ≥4 based on central pathologist scoring. Weight was required to be stable (<5% change in 3 months), and doses of GLP-1 RA and SGLT2i were required to be stable for ≥6 months and ≥30 days, respectively, prior to eligibility biopsy.
These findings support the clinical utility of combining resmetirom with established diabetes therapies while highlighting the potential for enhanced outcomes through modest weight management strategies in MASH (搜索) patients.